National Eye Institute Biorepository for Retinal Diseases

Related Clinical Trial
Propranolol and Von Hippel-Lindau Disease Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Assessment of Residual VHL Function in Tumors – Can it Predict the Patients’ Individual Course of Disease? Phase II Study of Vandetanib in Individuals With Kidney Cancer A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma Drivers of Hypoxia-induced Angiogenesis in Tumor Development Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors MyVHL: Patient Natural History Study Metabolic Mapping to Measure Retinal Metabolism Use of Tracking Devices to Locate Abnormalities During Invasive Procedures National Eye Institute Biorepository for Retinal Diseases Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Pazopanib in Von Hippel-Lindau (VHL) Syndrome 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Von Hippel-Lindau Disease Genetic Epidemiology Study Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 TKI 258 in Von Hippel-Lindau Syndrome (VHL) Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

Brief Title

National Eye Institute Biorepository for Retinal Diseases

Official Title

NEI Intramural Biorepository for Retinal Diseases

Brief Summary


      - To understand diseases of the retina and the eye, information is needed about people with
      and without such diseases. Researchers want to study these people and follow them over time.
      They also want to study body tissues and blood to understand the nature of eye disease.
      Studying genes, cells, and tissues may help them understand why some people get eye problems
      and others do not, or why some people respond to treatment while others do not. Researchers
      want to collect physical samples and personal data to develop a National Eye Institute


      - To collect health information and blood and tissue samples from people with and without eye
      diseases, to be used in research studies.


        -  Individuals of any age with different types of eye disease.

        -  Healthy volunteers with no history of eye disease.


        -  Participants may be recruited from National Eye Institute studies or may be referred
           from other sources.

        -  Participants will be screened with a physical exam and medical history. They will also
           have a full eye exam. Questions will be asked about family medical history, especially
           about eye disease.

        -  Blood samples will be collected. Other samples, such as saliva, tears, hair, stool, and
           urine, may be collected as needed. Adult participants may also provide a skin sample.

        -  Tissue or fluid from eye collected as part of eye care or treatment may also be added to
           the database.

        -  No treatment will be provided as part of this study.

Detailed Description

      This protocol establishes a clinical database and biospecimen repository for potential use in
      subsequent research projects approved by the NIH IRB, such as the identification of novel
      factors relevant to the pathogenesis, progression, and response to treatment of a variety of
      retinal conditions, particularly age-related macular degeneration (AMD) and diabetic
      retinopathy and their associated systemic correlates of disease.

      Objectives: This protocol provides for standardized collection of longitudinal clinical data
      and for serial collection, processing, and storage of a variety of biospecimens. The clinical
      data set and biospecimen repository may be used in subsequent potential research studies for
      purposes including identification of novel genetic factors, biomarkers, and experimental
      models associated with pathogenesis, progression, and response to treatment for various
      conditions of the retina and their associated systemic correlates of disease.

      Study Population: We plan to accrue up to 200 participants with AMD, 125 participants with
      diabetic retinopathy, 200 participants with other retinal diseases, and 125 participants
      without any retinal disease. A total of up to 650 participants may be enrolled.

      Design: This protocol is designed around prospective observation of multiple retinal diseases
      and suitable controls incorporating:

      Defined testing and ocular imaging on a standardized follow-up schedule; and

      Collection of biospecimens for research purposes for which sampling does not incur more than
      minimal risk to participants.

      Outcome Measures: Potential outcome measures for subsequent studies using this data set may
      include the interaction of key parameters of phenotype (such as visual acuity and retinal
      features on ocular imaging) with genetic variants and other biomarkers identified from
      biospecimens, and the characterization of new experimental models of eye health and disease.

Study Type


Primary Outcome

Interaction of key parameters of phenotype with genetic variants, and characterization of new experimental models of eye health and disease.


Age-Related Macular Degeneration

Study Arms / Comparison Groups

 Cohort 1
Description:  Participants with age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

June 18, 2012

Eligibility Criteria


        Participants will be eligible if they:

          -  Have the ability to understand and sign an informed consent or have a parent/legal
             guardian to do so if they are minor children.

          -  Manifest diagnosed or undiagnosed retinal disease(s), or could serve as an unaffected
             control suitable for comparison to participants with various retinal diseases,
             particularly AMD and diabetic retinopathy (taking into account matching factors such
             as age and past ocular history).


        Participants will not be eligible if they:

          -  Are unable or unwilling to give informed consent that includes collection and study of
             at least one peripheral blood sample.

          -  Are unable or unwilling to give informed consent that includes use of NIH medical
             records and clinical samples for research.

          -  Have a systemic disease that compromises the ability to provide adequate
             ophthalmologic examination or treatment.




2 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Tiarnan DL Keenan, M.D., (301) 402-4174, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

National Eye Institute (NEI)

Study Sponsor

Tiarnan DL Keenan, M.D., Principal Investigator, National Eye Institute (NEI)

Verification Date

April 12, 2022